Quantum Immunologic's FDA-Authorized Phase I / II Trial
Uploaded on Thursday 17 June 2010
DESCRIPTION
Quantum Immunologic's FDA-Authorized Phase I / II Trial focusing on dendritic cell cancer immunotherapy that targets OFA (oncofetal antigen) for Stage IV Breast Cancer Patients is underway. In addition to breast cancer, OFA is present in multiple cancer lines and activates the immune system to attack cancer cells on a targeted basis with less harsh side effects than chemo or radiation therapy.
DETAILS
Language: English
Length: 8+
Country: United States
